Vivoryon Therapeutics NV (FRA:05Y) Cash-to-Debt : 752.18 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Vivoryon Therapeutics NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vivoryon Therapeutics NV's cash to debt ratio for the quarter that ended in Dec. 2023 was 752.18.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vivoryon Therapeutics NV could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Vivoryon Therapeutics NV's Cash-to-Debt or its related term are showing as below:

FRA:05Y' s Cash-to-Debt Range Over the Past 10 Years
Min: 65.48 Med: 5376.09 Max: No Debt
Current: 752.18

During the past 13 years, Vivoryon Therapeutics NV's highest Cash to Debt Ratio was No Debt. The lowest was 65.48. And the median was 5376.09.

FRA:05Y's Cash-to-Debt is ranked better than
86.67% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs FRA:05Y: 752.18

Vivoryon Therapeutics NV Cash-to-Debt Historical Data

The historical data trend for Vivoryon Therapeutics NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vivoryon Therapeutics NV Cash-to-Debt Chart

Vivoryon Therapeutics NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

102.28

83.84

65.48

201.23

752.18

Vivoryon Therapeutics NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															65.48	136.26	201.23	497.44	752.18

Competitive Comparison of Vivoryon Therapeutics NV's Cash-to-Debt

For the Biotechnology subindustry, Vivoryon Therapeutics NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivoryon Therapeutics NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vivoryon Therapeutics NV's Cash-to-Debt falls into.

Vivoryon Therapeutics NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vivoryon Therapeutics NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.583	/	(0.038	+	0)
	=	752.18

Vivoryon Therapeutics NV's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	28.583	/	(0.038	+	0)
	=	752.18

Vivoryon Therapeutics NV (FRA:05Y) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vivoryon Therapeutics NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vivoryon Therapeutics NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivoryon Therapeutics NV (FRA:05Y) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivoryon Therapeutics NV (FRA:05Y) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VVY:Netherlands

Address

Weinbergweg 22, Halle, SN, DEU, 06120

Website

https://www.vivoryon.com

Vivoryon Therapeutics NV is a Germany-based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products include PQ912 and PQ1565. Geographically, the majority is from Greater China.

Vivoryon Therapeutics NV (FRA:05Y) Headlines

No Headlines